Posts tagged Abbreviated New Drug Applications (ANDA’s)
Developments in Obviousness Law and How It Could affect Your Invention

In the recent Acorda Therapeutics, Inc. v. Roxane Laboratories, Inc., No. 2017-2078 (Fed. Cir. Sept.10, 2018) decision, the Federal Circuit (the US appeals court for all patent cases) made a very harsh obviousness conclusion that may leave a big potential round of financing from Acorda investors out in the cold. I believe this decision, while directed to the life sciences specifically, is instructive in all areas of technology, and illustrates the importance of using an experienced patent attorney.

Read More